A296160 Stock Overview
A biotechnology company, engages in platform-based drug discovery and development activities. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Progen Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩6,500.00 |
52 Week High | ₩9,380.00 |
52 Week Low | ₩5,550.00 |
Beta | 0 |
1 Month Change | -0.76% |
3 Month Change | -4.41% |
1 Year Change | -21.31% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 62.09% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
A296160 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | 1.6% | 1.5% | -1.5% |
1Y | -21.3% | 22.9% | -10.9% |
Return vs Industry: A296160 underperformed the KR Life Sciences industry which returned 22.9% over the past year.
Return vs Market: A296160 underperformed the KR Market which returned -10.9% over the past year.
Price Volatility
A296160 volatility | |
---|---|
A296160 Average Weekly Movement | 3.4% |
Life Sciences Industry Average Movement | 10.2% |
Market Average Movement | 6.6% |
10% most volatile stocks in KR Market | 12.8% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A296160 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A296160's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | n/a | n/a | www.progen.co.kr |
Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes.
Progen Co., Ltd. Fundamentals Summary
A296160 fundamental statistics | |
---|---|
Market cap | ₩75.09b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A296160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A296160 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A296160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/02 03:18 |
End of Day Share Price | 2025/01/02 00:00 |
Earnings | N/A |
Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Progen Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|